Andreas Kyprianou, MD
Pulmonary Disease · Largo, FLNPI 1639126105
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,751 of the $38,906 with a category attached, or 68.8%. 37 manufacturers reported payments, led by Boehringer Ingelheim at 42.2% of the total. Reporting peaked in 2019 at $24,654 and has fallen 97.7% since, to $562 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $136.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$16K
- Mylan Specialty L.p.$14K
- Actelion Pharmaceuticals US, Inc.$4K
- AstraZeneca$767
- GSK$684
- Insmed, Inc.$670
- plus $2K from 31 others
What the payments were for
- Consulting fees$4,18711%
- Speaking & faculty fees$26,75169%
- Travel & lodging$1,4324%
- Food & beverage$6,17316%
- Education$3631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 35 | $16,416 |
| Mylan Specialty L.p. | 44 | $14,005 |
| Actelion Pharmaceuticals US, Inc. | 15 | $4,199 |
| AstraZeneca | 33 | $767 |
| GSK | 34 | $684 |
| Insmed, Inc. | 17 | $670 |
| Sunovion Pharmaceuticals Inc. | 28 | $377 |
| United Therapeutics Corporation | 5 | $159 |
| Stryker | 1 | $147 |
| Abiomed | 4 | $136 |
| Genentech USA, Inc. | 9 | $128 |
| Johnson & Johnson | 1 | $122 |
| Grifols USA, LLC | 3 | $120 |
| Sanofi | 6 | $112 |
| Philips North America LLC | 5 | $99 |
| Mallinckrodt Hospital Products Inc. | 3 | $78 |
| Verona Pharma, Inc. | 3 | $70 |
| Circassia Inc. | 4 | $60 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| Inspire Medical Systems, Inc. | 1 | $54 |
| Electromed, Inc. | 5 | $47 |
| Watermark Medical, Inc. | 2 | $47 |
| Shire North American Group Inc | 2 | $39 |
| Mayne Pharma Commercial LLC | 3 | $35 |
| Gilead | 2 | $34 |
| Novartis | 2 | $33 |
| Merck | 2 | $31 |
| UCB, Inc. | 2 | $30 |
| Advanced Respiratory, Inc | 2 | $26 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $19 |
| Veran Medical Technologies, Inc. | 1 | $15 |
| Vapotherm Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$13,605
- OPSUMIT$3,713
- UPTRAVI$3,713
- NUCALA$231
- FLOWTRIEVER CATHETER, S$147
- CT THROMBECTOMY SYSTEM KIT$147
- TAGRISSO$125
- Perforomist$125
- Monarch Platform$122
- TEZSPIRE$106
How this compares
$38,906 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $32,366 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,466 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $11,071 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $684 | $43,43750 claims |
| AstraZenecaBreztri Aerosphere | $767 | $15,46625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Largo
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.